Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To investigate the potential therapeutic role of adalimumab in treating COVID-19 cases in combination therapy with remdesivir and dexamethasone

Next Previous
Trial Profile

To investigate the potential therapeutic role of adalimumab in treating COVID-19 cases in combination therapy with remdesivir and dexamethasone

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 08 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary) ; Dexamethasone; Interferon beta-1a; Lopinavir/ritonavir; Remdesivir
  • Indications COVID 2019 infections; COVID-19 pneumonia; SARS-CoV-2 acute respiratory disease
  • Focus Therapeutic Use

Most Recent Events

  • 08 Oct 2021 New trial record
  • 01 Oct 2021 Primary endpoint (rate of mortality) has not been met according to the results published in the International Immunopharmacology
  • 01 Oct 2021 Primary endpoint (requiring invasive mechanical ventilation, the necessity of admission to the Intensive Care Unit (ICU) has not been met according to the results published in the International Immunopharmacology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top